AR098880A2 - Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión - Google Patents
Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusiónInfo
- Publication number
- AR098880A2 AR098880A2 ARP140104816A ARP140104816A AR098880A2 AR 098880 A2 AR098880 A2 AR 098880A2 AR P140104816 A ARP140104816 A AR P140104816A AR P140104816 A ARP140104816 A AR P140104816A AR 098880 A2 AR098880 A2 AR 098880A2
- Authority
- AR
- Argentina
- Prior art keywords
- mmol
- concentration
- electrolyte
- protective solution
- contained
- Prior art date
Links
- 230000001681 protective effect Effects 0.000 title abstract 5
- 210000000056 organ Anatomy 0.000 title abstract 2
- 230000010412 perfusion Effects 0.000 title abstract 2
- 230000010410 reperfusion Effects 0.000 title abstract 2
- 239000003792 electrolyte Substances 0.000 abstract 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- KBOJOGQFRVVWBH-ZETCQYMHSA-N N-acetyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1 KBOJOGQFRVVWBH-ZETCQYMHSA-N 0.000 abstract 2
- 229940009098 aspartate Drugs 0.000 abstract 2
- 150000002500 ions Chemical class 0.000 abstract 2
- 150000004702 methyl esters Chemical class 0.000 abstract 2
- CFAMAWCPWJCAFR-UHFFFAOYSA-N n-hydroxy-3,4-dimethoxy-n-methylbenzamide Chemical compound COC1=CC=C(C(=O)N(C)O)C=C1OC CFAMAWCPWJCAFR-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 108010016626 Dipeptides Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical class O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000005138 cryopreservation Methods 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- -1 lysine cation Chemical class 0.000 abstract 1
- 150000002668 lysine derivatives Chemical class 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Abstract
Una solución protectora para prevenir daños isquémicos en los órganos, o en sistemas celulares aislados, o en componentes de tejido después de la perfusión, operación, trasplante, o crio-conservación y subsiguiente reperfusión, que comprende un electrolito seleccionado del grupo que consiste en iones alcalinos y iones alcalino-térreos, un buffer, un poliol y/o un sacárido, en donde dicha solución tiene una osmolaridad de 290 mosm/L a 350 mosm/L, como también un pH con un valor de 6,8 a 7,4 y comprende ácido 3,4 dimetoxi-N-metiIbenzohidroxámico y/o una sal del mismo, dicha composición además comprende N-acetilhistidina como un agente buffer en combinación con arginina, con un contenido aniónico de aspartato, en la cual el ácido 3,4-dimetoxi-N-metilbenzohidroxámico y/o una sal del mismo está comprendido en una cantidad de hasta 10 mmol/L, en la cual la N-acetilhistidina está comprendida en una concentración de 30 mmol/L a 265 mmol/L, en la cual el sodio está contenido deliberadamente como un electrolito a una concentración de 10 mmol/L a 80 mmol/L, en la cual el potasio está contenido deliberadamente como un electrolito a una concentración de 5 mmol/L a 25 mmol/L, en la cual el magnesio está contenido deliberadamente como un electrolito a una concentración de 3,5 mmol/L a 27 mmol/L, en la cual el calcio está contenido deliberadamente como un electrolito a una concentración de 0,005 mmol/L a 0,095 mmol/L, en donde el aspartato está contenido a una concentración de hasta 140 mmol/L, y en donde el a-cetoglutarato está contenido a una concentración de 1 mmol/L a 9 mmol/L. Reivindicación 2: Solución protectora de acuerdo con la reivindicación 1, caracterizada porque comprende una adición de un derivado del ácido 6-hidroxi-2,5,7,8-tetrametilcromán-2-carboxílico, preferentemente del metil éster respectivo. Reivindicación 3: Solución protectora de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizada porque tiene un contenido de catión de lisina y/o derivado de lisina, preferentemente dipéptidos que contienen lisina. Reivindicación 5: Solución protectora de acuerdo con una cualquiera de las reivindicaciones 2 a 4, caracterizada porque el derivado del ácido 6-hidroxi-2,5,7,8-tetrametiIcromán-2-carboxílico, preferentemente como el derivado de metil éster, está comprendido en una concentración de hasta aproximadamente 10 mmoI/L.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10222561A DE10222561B4 (de) | 2002-05-17 | 2002-05-17 | Protektive Lösung zur Verhinderung von Ischämieschäden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098880A2 true AR098880A2 (es) | 2016-06-22 |
Family
ID=29265373
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101726A AR039819A1 (es) | 2002-05-17 | 2003-05-16 | Solucion protectora para evitar danos isquemicos en organos |
| ARP140104816A AR098880A2 (es) | 2002-05-17 | 2014-12-19 | Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101726A AR039819A1 (es) | 2002-05-17 | 2003-05-16 | Solucion protectora para evitar danos isquemicos en organos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7977383B2 (es) |
| EP (2) | EP1362511B1 (es) |
| JP (1) | JP4603246B2 (es) |
| KR (2) | KR101014990B1 (es) |
| CN (1) | CN100448440C (es) |
| AR (2) | AR039819A1 (es) |
| AT (2) | ATE446676T1 (es) |
| BR (1) | BRPI0301159B8 (es) |
| CA (1) | CA2429097C (es) |
| DE (4) | DE10262084B4 (es) |
| DK (1) | DK1859679T3 (es) |
| ES (2) | ES2335145T3 (es) |
| MX (1) | MXPA03004315A (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10262084B4 (de) | 2002-05-17 | 2009-12-24 | Dr. Franz Köhler Chemie GmbH | Protektive Lösung zur Verhinderung von Ischämieschäden |
| US8029815B2 (en) | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| WO2005115141A1 (ja) * | 2004-05-26 | 2005-12-08 | National University Corporation Kagawa University | 希少糖を利用した細胞・組織・臓器保存液及び該液を用いる保存方法 |
| DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
| EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| US8835104B2 (en) | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
| AU2011295629B2 (en) * | 2010-09-01 | 2014-05-01 | Organ Transport Pty Ltd | Perfusion composition |
| EP3662750A1 (en) | 2011-04-07 | 2020-06-10 | Fenwal, Inc. | Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates |
| BRPI1101935B1 (pt) * | 2011-04-15 | 2017-12-12 | Universidade Federal De Minas Gerais | Antioxidant composition for preservation of organs and fabrics |
| DE102012005177A1 (de) | 2012-03-16 | 2013-09-19 | Bitop Ag | Organlagerlösung |
| NL2010010C2 (en) * | 2012-12-19 | 2014-06-23 | Sulfateq B V | Compounds for protection of cells. |
| CN103238586B (zh) * | 2013-03-28 | 2014-03-26 | 辽宁亿灵科创生物医药科技有限公司 | 一种心肌脏器保存液制备方法 |
| EP2821081A1 (en) * | 2013-07-05 | 2015-01-07 | ResuSciTec GmbH | Protective solution for preventing or reducing reperfusion injury of the brain and the whole body |
| HRP20220112T1 (hr) | 2013-12-24 | 2022-04-15 | Virginia Commonwealth University | Upotreba oksidacijskog sulfata kolesterola (ocs) za liječenje akutne insuficijencije jetre |
| ES3048139T3 (en) | 2016-05-01 | 2025-12-09 | Univ California | Glutarate compounds for treating ischemia-reperfusion injuries |
| DE102016125414A1 (de) | 2016-12-22 | 2018-06-28 | Bitop Ag | Zusammensetzung enthaltend N-Acetyldiaminobuttersäure |
| CN110536687B (zh) * | 2018-03-27 | 2022-12-16 | 华东理工大学 | N-羟基吡啶酮类化合物及其用途 |
| KR20200069995A (ko) | 2018-12-08 | 2020-06-17 | 이은지 | 접이식 빗자루 |
| WO2021041836A1 (en) * | 2019-08-28 | 2021-03-04 | The Regents Of The University Of Michigan | Preservation of organs for transplant and non-transplant surgeries |
| US20230241076A1 (en) * | 2020-06-29 | 2023-08-03 | The Regents Of The University Of Michigan | Histone-acetylation-modulating agents for the treatment and prevention of organ injury |
| EP4248959A1 (en) * | 2022-03-22 | 2023-09-27 | Dr. Franz Köhler Chemie GmbH | Preparation for reduction of pathological iron overload |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH639270A5 (de) | 1978-12-14 | 1983-11-15 | Koehler Franz Dr Chemie Kg | Protektive loesung fuer herz und niere. |
| DE3168925D1 (en) * | 1980-12-23 | 1985-03-28 | Koehler Chemie Dr Franz | Protective solution for heart and kidney, and manufacturing process |
| US4419365A (en) * | 1981-12-21 | 1983-12-06 | Ciba-Geigy Corporation | Method of treating Alzheimer's disease |
| US4562006A (en) * | 1984-01-11 | 1985-12-31 | Warner-Lambert Company | Cycloheptadiene derivatives |
| US4607053A (en) * | 1984-05-17 | 1986-08-19 | E. R. Squibb & Sons, Inc. | Arylhydroxamates useful as antiallergy agents |
| US4604407A (en) * | 1985-04-04 | 1986-08-05 | E. R. Squibb & Sons, Inc. | Hydroxamates |
| US4927571A (en) * | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| DK36389A (da) * | 1988-02-05 | 1989-08-06 | Eastman Kodak Co | Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion |
| JPH11514326A (ja) * | 1990-03-30 | 1999-12-07 | バイオメディカル フロンティアーズ インコーポレイテッド | 液体蘇生用医薬物 |
| WO1991015215A1 (en) | 1990-03-30 | 1991-10-17 | Biomedical Frontiers, Inc. | Fluid resuscitation |
| JP2768799B2 (ja) * | 1990-04-12 | 1998-06-25 | 株式会社大塚製薬工場 | 心筋保護液 |
| EP0509066A4 (en) * | 1990-09-10 | 1992-11-25 | Austin L. Shug | Composition and method for protecting the heart during reperfusion |
| JP2860301B2 (ja) | 1990-09-19 | 1999-02-24 | ヘキスト・マリオン・ルセル株式会社 | 臓器保存用溶液 |
| GB9024820D0 (en) * | 1990-11-15 | 1991-01-02 | Davies Michael J | Pharmaceutical compositions |
| US5498427A (en) * | 1990-11-20 | 1996-03-12 | Pasteur Merieux Serums Et Vaccines | Solutions for the perfusion, preservation and reperfusion of organs |
| US5290766A (en) * | 1991-02-18 | 1994-03-01 | The National Heart Foundation Of New Zealand | Cardioplegic compositions |
| US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
| WO1995005076A1 (en) * | 1993-08-12 | 1995-02-23 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
| US6321909B1 (en) * | 1997-02-13 | 2001-11-27 | Sky High, Llc | System for storing polyethylene glycol solutions |
| EP0938896A1 (en) * | 1998-01-15 | 1999-09-01 | Novartis AG | Autoclavable pharmaceutical compositions containing a chelating agent |
| US6365338B1 (en) * | 1999-04-27 | 2002-04-02 | David A. Bull | Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source |
| DE10262084B4 (de) | 2002-05-17 | 2009-12-24 | Dr. Franz Köhler Chemie GmbH | Protektive Lösung zur Verhinderung von Ischämieschäden |
-
2002
- 2002-05-17 DE DE10262084A patent/DE10262084B4/de not_active Expired - Fee Related
- 2002-05-17 DE DE10222561A patent/DE10222561B4/de not_active Expired - Fee Related
-
2003
- 2003-05-14 ES ES07012466T patent/ES2335145T3/es not_active Expired - Lifetime
- 2003-05-14 AT AT07012466T patent/ATE446676T1/de active
- 2003-05-14 EP EP03010783A patent/EP1362511B1/de not_active Expired - Lifetime
- 2003-05-14 DE DE50313573T patent/DE50313573D1/de not_active Expired - Lifetime
- 2003-05-14 EP EP07012466A patent/EP1859679B1/de not_active Expired - Lifetime
- 2003-05-14 DE DE50312079T patent/DE50312079D1/de not_active Expired - Lifetime
- 2003-05-14 AT AT03010783T patent/ATE503383T1/de active
- 2003-05-14 DK DK07012466.4T patent/DK1859679T3/da active
- 2003-05-14 ES ES03010783T patent/ES2362867T3/es not_active Expired - Lifetime
- 2003-05-16 MX MXPA03004315A patent/MXPA03004315A/es active IP Right Grant
- 2003-05-16 BR BRPI0301159A patent/BRPI0301159B8/pt not_active IP Right Cessation
- 2003-05-16 CA CA2429097A patent/CA2429097C/en not_active Expired - Lifetime
- 2003-05-16 AR ARP030101726A patent/AR039819A1/es not_active Application Discontinuation
- 2003-05-16 KR KR1020030031134A patent/KR101014990B1/ko not_active Expired - Lifetime
- 2003-05-16 US US10/438,977 patent/US7977383B2/en not_active Expired - Lifetime
- 2003-05-16 JP JP2003138927A patent/JP4603246B2/ja not_active Expired - Fee Related
- 2003-05-16 CN CNB031438474A patent/CN100448440C/zh not_active Expired - Lifetime
-
2010
- 2010-08-11 KR KR1020100077083A patent/KR101061293B1/ko not_active Expired - Fee Related
-
2011
- 2011-06-02 US US13/152,056 patent/US9603354B2/en not_active Expired - Fee Related
-
2014
- 2014-12-19 AR ARP140104816A patent/AR098880A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0301159B1 (pt) | 2018-05-15 |
| ES2335145T3 (es) | 2010-03-22 |
| KR101014990B1 (ko) | 2011-02-16 |
| MXPA03004315A (es) | 2005-02-14 |
| EP1859679B1 (de) | 2009-10-28 |
| DK1859679T3 (da) | 2010-03-15 |
| DE10222561B4 (de) | 2009-12-10 |
| BR0301159A (pt) | 2004-08-17 |
| ATE446676T1 (de) | 2009-11-15 |
| ATE503383T1 (de) | 2011-04-15 |
| US9603354B2 (en) | 2017-03-28 |
| KR101061293B1 (ko) | 2011-08-31 |
| CA2429097C (en) | 2013-06-18 |
| CA2429097A1 (en) | 2003-11-17 |
| JP4603246B2 (ja) | 2010-12-22 |
| KR20100093023A (ko) | 2010-08-24 |
| EP1362511B1 (de) | 2011-03-30 |
| JP2004002418A (ja) | 2004-01-08 |
| US7977383B2 (en) | 2011-07-12 |
| US20030215781A1 (en) | 2003-11-20 |
| ES2362867T3 (es) | 2011-07-14 |
| DE10262084B4 (de) | 2009-12-24 |
| AR039819A1 (es) | 2005-03-02 |
| BRPI0301159B8 (pt) | 2021-05-25 |
| CN1480132A (zh) | 2004-03-10 |
| EP1362511A1 (de) | 2003-11-19 |
| DE10222561A1 (de) | 2003-12-04 |
| EP1859679A1 (de) | 2007-11-28 |
| KR20030089495A (ko) | 2003-11-21 |
| CN100448440C (zh) | 2009-01-07 |
| DE50312079D1 (de) | 2009-12-10 |
| US20110300237A1 (en) | 2011-12-08 |
| DE50313573D1 (de) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR098880A2 (es) | Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión | |
| JP2014516981A5 (es) | ||
| AR072250A1 (es) | COMPOSICIONES DE INSULINA DE ACCION SUPERRAPIDA. BOMBA DE INSULINA, DISPENSADOR. SISTEMA DE LAZO CERRADO. METODO PARA PREPARAR COMPOSICIoN, USO. COMBINACION. KIT. | |
| CL2017002488A1 (es) | Formulación farmacéutica estable para administración intratecal que comprende una proteína arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que además puede contener un agente estabilizante; contenedor que comprende dicha formulación; uso para tratar la enfermedad leucodistrofia metacrómatica (mld). (divisional solicitud 3654-2012) | |
| AR093662A1 (es) | Agentes crioprotectores, composiciones crioprotectoras y criopreservadas, sus usos y metodos de criopreservacion | |
| CL2017000998A1 (es) | Composición que comprende un agente de control biológico de la especie bacillus subtilis y un fungicida del grupo de inhibidores de la mitosis y la división celular, tal como fenamidona. (divisional solicitud 3272-2014) | |
| Guan et al. | Cryopreservation of zebrafish (Danio rerio) oocytes using improved controlled slow cooling protocols | |
| CL2008003762A1 (es) | Composicion concentrada en suspension acuosa para proteccion de cultivos, que comprende un compuesto activo y como agentes estabilizadores, un disperzante no ionico y un dsipersante anionico y agua; metodos para preparacion de dicha composicion y usos de la misma, para el cuidado de cultivos de interes. | |
| RU2010146038A (ru) | Фармацевтические составы для местного применения, содержащие низкую концентрацию бензоилпероксида в суспензии в воде и смешивающимся с водой органическом растворителе | |
| Ahmed et al. | Supplementation of l-tryptophan (an aromatic amino acid) in tris citric acid extender enhances post-thaw progressive motility, plasmalemma, mitochondrial membrane potential, acrosome, and DNA integrities, and in vivo fertility rate of buffalo (Bubalus bubalis) bull spermatozoa | |
| AR095964A1 (es) | Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil | |
| JP3694730B2 (ja) | 組織の冷却保存液 | |
| CN106538510B (zh) | 番茄红素和芝麻酚配伍在家畜精液冷冻保存剂中的应用 | |
| Tomalty et al. | Kidney preservation at subzero temperatures using a novel storage solution and insect ice-binding proteins | |
| MY181282A (en) | Solutions for increasing the stability and shelf life of an organ and tissue preservation solution | |
| PE20081320A1 (es) | Composicion microbicida acuosa estabilizada contra la degradacion por luz ultravioleta | |
| PE20030729A1 (es) | Metodos para conservar soluciones oftalmicas y soluciones oftalmicas conservadas | |
| Gambert et al. | Deep hypothermia during ischemia improves functional recovery and reduces free-radical generation in isolated reperfused rat heart | |
| Buranaamnuay et al. | The in vitro quality of frozen-thawed Asian elephant (Elephas maximus) spermatozoa in semen supplemented with Equex STM paste and oxytocin during and after cryopreservation | |
| AR069939A1 (es) | Solucion de irrigacion quirurgica estabilizada que contiene glicerofosfato | |
| JP2007224004A (ja) | 超小型豚の人工授精用精液の希釈保存剤。 | |
| MX2007000082A (es) | Compuesto de clatrato, metodo para controlar concentracion de solucion de ingrediente activo quimico agricola, acuosa y formulacion quimica agricola. | |
| GT200400072A (es) | Composicion de suspension agroquimica acuosa. | |
| RU2010146519A (ru) | Композиция биологически активных препаратов для повышения выживаемости осетровых рыб при искусственном воспроизводстве | |
| Mehdipour et al. | Optimized vapor‑phase cooling and mitochondria‑targeted MitoPBN supplementation enhance cryosurvival of rooster sperm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |